Patents by Inventor Rajkumar Ganesan

Rajkumar Ganesan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250145711
    Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3?, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Application
    Filed: September 10, 2024
    Publication date: May 8, 2025
    Inventors: Adam Zwolak, Raymond Brittingham, Scott R. Brodeur, Rajkumar Ganesan, Sherry Lynn La Porte, Jinquan Luo, Fang Yi, Colleen M. Kane, Triveni K. Bhatt
  • Patent number: 12264197
    Abstract: Anti-V?17/anti-CD123 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: April 1, 2025
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Manuel Alejandro Sepulveda
  • Publication number: 20250092134
    Abstract: Anti-V?17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Application
    Filed: November 1, 2022
    Publication date: March 20, 2025
    Inventors: Rajkumar Ganesan, IqbaI S. GREWAL, Sanjaya SINGH, Michael Riis HANSEN
  • Publication number: 20250066474
    Abstract: Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Application
    Filed: November 13, 2024
    Publication date: February 27, 2025
    Inventors: Kyle J. Bednar, Naresh Kumar, Sanjaya Singh, Danlin Yang, Rajkumar Ganesan
  • Publication number: 20250043019
    Abstract: Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof.
    Type: Application
    Filed: August 21, 2024
    Publication date: February 6, 2025
    Inventors: Rajkumar Ganesan, Anna Kuchnio, Cassandra L. Lowenstein, Ulrike Philippar, Sanjaya Singh, Nele Vloemans, Danlin Yang
  • Publication number: 20250043004
    Abstract: Provided herein are trispecific antibodies or antigen binding fragments thereof that bind to V?17, CD28 and another target (e.g., a cancer antigen, such as BCMA or PSMA) are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Application
    Filed: October 10, 2024
    Publication date: February 6, 2025
    Inventors: Rajkumar GANESAN, Michael Riis HANSEN, Iqbal S. GREWAL, Sanjaya SINGH
  • Patent number: 12180278
    Abstract: Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: December 31, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Kyle J. Bednar, Naresh Kumar, Sanjaya Singh, Danlin Yang, Rajkumar Ganesan
  • Publication number: 20240424130
    Abstract: Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) V?9 (TRGV9), TCR V?2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.
    Type: Application
    Filed: August 22, 2024
    Publication date: December 26, 2024
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: RAJKUMAR GANESAN, IQBAL S. GREWAL, SANJAYA SINGH, MICHAEL RIIS HANSEN
  • Patent number: 12173083
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: December 24, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj Gupta
  • Publication number: 20240384231
    Abstract: The present disclosure provides methods for generating stem-cell like memory T (TSCM) cells. The present disclosure also provides cells, pharmaceutical compositions, and their uses in adoptive immunotherapy for treatment of a disease, such as cancer.
    Type: Application
    Filed: April 7, 2022
    Publication date: November 21, 2024
    Inventors: Madhusudhanan SUKUMAR, Rajkumar GANESAN, Sanjaya SINGH, Tamas ORAVECZ
  • Patent number: 12134658
    Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: November 5, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar Ganesan, Adam Zwolak, Ian White, Ninkka Tamot, Paul B. Harvilla, Rajitha Doddareddy, Sanjaya Singh, Martin Jack Borrok, III
  • Publication number: 20240360421
    Abstract: Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (iPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.
    Type: Application
    Filed: April 9, 2024
    Publication date: October 31, 2024
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Iqbal S GREWAL, Rajkumar GANESAN, Sanjaya SINGH
  • Patent number: 12129310
    Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: October 29, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Sanjaya Singh, Rajkumar Ganesan, Jun Chen, Iqbal S. Grewal
  • Publication number: 20240336674
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: January 26, 2024
    Publication date: October 10, 2024
    Inventors: Leo THOMAS, Rachel Rebecca BARRETT, Kristin Laura BOVAT, Rajkumar GANESAN, Priyanka GUPTA, Fei HAN, Dongmei LIU, Juergen PRESTLE, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Helen Haixia WU, Nina ZIPPEL
  • Patent number: 12103977
    Abstract: Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: October 1, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Anna Kuchnio, Cassandra L. Lowenstein, Ulrike Philippar, Sanjaya Singh, Nele Vloemans, Danlin Yang
  • Patent number: 12084501
    Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3?, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: September 10, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Adam Zwolak, Raymond Brittingham, Scott R. Brodeur, Rajkumar Ganesan, Sherry Lynn La Porte, Jinquan Luo, Fang Yi, Colleen M. Kane, Triveni K. Bhatt
  • Publication number: 20240293453
    Abstract: The invention provides antigen binding domains that bind myeloid cell surface antigen CD33 protein comprising the antigen binding domains that bind CD33, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 5, 2024
    Inventors: Patrick John DOONAN, Rajkumar GANESAN, Mehabaw Getahun DEREBE, Sathyadevi VENKATARAMANI, Sanjaya SINGH, Iqbal S. GREWAL, Karla R. WIEHAGEN
  • Patent number: 12077585
    Abstract: Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: September 3, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, John Lee, Jinquan Luo, Theresa McDevitt, Fei Shen, Degang Song, Raymond Brittingham, Sathyadevi Venkataramani, Sanjaya Singh, Yonghong Zhao, Fang Yi, Sherry Lynn La Porte
  • Patent number: 12076413
    Abstract: Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) V?9 (TRGV9), TCR V?2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: September 3, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh, Michael Riis Hansen
  • Patent number: 12077592
    Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: September 3, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Ricardo Attar, Rajkumar Ganesan, Francois Gaudet, Bradley J. Heidrich, Carmen Baca Jones, John Lee, Yingzhe Li, Sanjaya Singh, Sathya Venkataramani